NCT01632306View on ClinicalTrials.gov

A Study of LY2090314 and Chemotherapy in Participants With Metastatic Pancreatic Cancer

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

March 31, 2013

Primary Completion Date

June 30, 2015

Study Completion Date

June 30, 2015

Conditions
Pancreatic Cancer
Interventions
DRUG

LY2090314

LY2090314 administered IV

DRUG

FOLFOX

FOLFOX administered IV

DRUG

Gemcitabine

Gemcitabine administered IV

DRUG

Nab-paclitaxel

Nab-paclitaxel administered IV

Trial Locations (2)

32224

Mayo Clinic of Jacksonville, Jacksonville

55905

Mayo Clinic, Rochester

Sponsors

Collaborators (1)

Mayo Clinic
All Listed Sponsors
collaborator

Mayo Clinic

OTHER

lead

Eli Lilly and Company

INDUSTRY